UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 13, 2026

Dare Bioscience, Inc.

DARÉ BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware

~~001-36395~~

~~20-4139823~~

001-36395

20-4139823

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

(State or other jurisdictionof incorporation)

(CommissionFile Number)

(I.R.S. EmployerIdentification No.)

3655 Nobel Drive, Suite 260

San Diego, CA 92122

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (858) 926-7655

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock	DARE	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐ ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ¨

Item 7 3.01 ~~Regulation~~Notice FDof ~~Disclosure~~Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

~~Furnished as~~On ~~Exhibit~~July 9913, 2026, Dare Biosciences, Inc.1 to(the ~~this~~“Company”) ~~report~~was isnotified aby ~~copy~~the ofListing aQualifications ~~corporate~~Staff ~~presentation~~(the “Staff”) of ~~Daré~~The ~~Bioscience,~~Nasdaq ~~Inc.~~Stock Market LLC (“~~Daré~~Nasdaq”) orthat, because the “ Company”)’s ~~dated~~Form ~~July~~10-Q 13for the period ended March 31, 2026, ~~which~~reported isstockholders’ ~~incorporated~~equity ~~herein~~of byless ~~reference~~than $2.5 ~~The~~million and, as of July 13, 2026, the Company ~~intends~~did tonot ~~use~~meet the ~~presentation~~alternative ~~and its~~requirements ~~contents~~of $35 million in ~~various~~market ~~meetings~~value ~~with~~of listed securities ~~market~~or ~~participants~~$500,000 ~~and~~in ~~others~~net income from continuing operations, ~~commencing~~the onCompany ~~July~~no 13longer complies with Nasdaq Listing Rule 5550(b) (the “Rule”) and, ~~2026~~as such, the Company’s common stock is subject to delisting from Nasdaq unless the Company timely requests a hearing to address the deficiency before a Nasdaq Hearing Panel (the “Panel”).

The Company ~~plans~~intends to ~~make~~timely request a ~~copy~~hearing ofbefore the ~~presentation~~Panel, ~~available~~which inrequest ~~the~~will ~~“Investors”~~stay ~~section~~the ofsuspension ~~its~~and ~~website~~delisting ~~(https://ir.darebioscience.com), on~~of the ~~page~~Company’s ~~titled~~common ~~“Presentations,~~stock ~~Events~~at &least ~~Webcasts,”~~pending ~~under~~ the ~~heading~~issuance ~~“Presentations.”~~of ~~Information~~the ~~contained in,~~Panel’s ordecision ~~that~~following ~~can~~the behearing ~~accessed~~and ~~through,~~ the ~~Company’s~~expiration ~~website~~of or any ~~other~~extension ~~website~~period ~~referenced~~that inmay ~~the~~be ~~presentation~~granted ~~is not incorporated~~ by ~~reference~~the ~~into this report~~Panel.

~~The information~~There incan ~~this~~be ~~Item~~no ~~7.01~~assurance ~~and~~that ~~Exhibit~~the ~~99.1~~Panel towill ~~this~~grant ~~report~~the isCompany’s ~~being~~request ~~furnished~~for ~~and~~an ~~shall~~extension ~~not be deemed~~ to beevidence ~~“filed”~~compliance ~~for purposes~~with ~~of Section 18 of~~ the ~~Securities Exchange Act of 1934~~Rule, ~~as amended (the “Exchange Act”),~~ or ~~otherwise~~if ~~subject~~any tosuch ~~the liabilities~~extension ofperiod ~~that~~is ~~section~~granted, ~~nor~~that ~~shall~~the ~~such~~Company ~~information~~will beregain ~~deemed~~compliance towith ~~be incorporated by reference into any filing under~~ the ~~Exchange Act~~Rule orwithin ~~the~~such ~~Securities~~extension ~~Act of 1933~~period, ~~as amended, whether made before~~ or ~~after~~that the ~~date~~Company ~~hereof,~~will ~~regardless~~be ofsuccessful ~~any general incorporation by reference language~~ in ~~any~~otherwise ~~such~~maintaining ~~filing, except as~~ the ~~Company~~listing ~~expressly~~of ~~sets~~its ~~forth~~common bystock ~~specific~~on ~~reference in such filing~~Nasdaq.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Daré Bioscience corporate presentation, dated July 13, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~DARÉ BIOSCIENCE, INC.~~

DARÉ BIOSCIENCE, INC.

Dated: July 13, 2026

By:

/s/ Sabrina Martucci Johnson

Dated: July 17, 2026

By:

/s/ Sabrina Martucci Johnson

~~Name:~~

~~Sabrina Martucci Johnson~~

Name:

Sabrina Martucci Johnson

~~Title:~~

~~President and Chief Executive Officer~~

Title:

President and Chief Executive Officer

-3-

Filing Compare · Dare Bioscience, Inc.